FindTrial
Sign In

Maternal telomere length as novel biomarker to assess the risk of SB in offspring.

Maternal telomere length as novel biomarker to assess the risk of SB in offspring. - Maternal telomere length and risk of SB in offspring.

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON49698
Enrollment
100
Registered
2020-12-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neural tube defect Spina Bifida

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Cases - At least 18 years of age. - Singleton pregnancy. - Pregnant or gave birth to a child with SB between January 2005 and January 2021. - Familiar with the spoken and written Dutch language Controls - At least 18 years of age - Singleton pregnancy - Pregnant or gave birth to a child without congenital malformations between June 2003 until January 2010 - Familiar with the spoken and written Dutch language

Exclusion criteria

Exclusion criteria: Not applicable.

Design outcomes

Primary

MeasureTime frame
The difference in TL in cases and controls to assess the risk of SB in the offspring. *—

Secondary

MeasureTime frame
Our secondary study parameters are to assess the relation between maternal TL and obstetrical (pregnancy course and outcome), environmental risk factors (such as lifestyle, diet, obesity), and biochemical markers of oxidative stress.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)